International Pediatric Nephrology Association

Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Friday, November 3, 2023
University of Minnesota Medical School, EGFR, Key finding attacks, Heart Protection Study, Kidney failure, Kidney, University Center, SGLT2, Kidney disease, Society, American Society of Nephrology, Quality of life, Disease, Division, Clinical trial, ASN, Jay Traver, Abstract, The New England Journal of Medicine, Overload, University, Immunoglobulin A, Focal segmental glomerulosclerosis, Therapy, Patient, Death, International Pediatric Nephrology Association, SAN, Proteinuria, Pharmaceutical industry, Dietary supplement, Medical device, IgA nephropathy, Irbesartan, PROTECT, Nephrology, FSGS, Lancet

SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced additional data from two pivotal clinical studies demonstrating sparsentan has the potential to preserve kidney function and significantly delay time to kidney failure compared to an active comparator, suggesting long-term benefits in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). Data from the Phase 3 PROTECT and DUPLEX Studies were presented as late-breaking oral presentations at the American Society of Nephrology (ASN) Kidney Week 2023 and simultaneously published in The Lancet (PROTECT) and The New England Journal of Medicine (DUPLEX).

Key Points: 
  • Data from the Phase 3 PROTECT and DUPLEX Studies were presented as late-breaking oral presentations at the American Society of Nephrology (ASN) Kidney Week 2023 and simultaneously published in The Lancet (PROTECT ) and The New England Journal of Medicine (DUPLEX) .
  • The absolute overall change in kidney function from baseline to the end of the study for patients treated with FILSPARI was -5.8 mL/min/1.73m2 compared to -9.5 mL/min/1.73m2 with irbesartan.
  • Treatment with FILSPARI demonstrated lower rates of the composite endpoint of 40% decline in eGFR, kidney failure or death compared to irbesartan.
  • Sparsentan showed a consistent and sustained achievement of complete remission of proteinuria in 18.5% of patients on sparsentan vs. 7.5% for irbesartan.

Dr. Verna Yiu appointed to EPCOR Board of Directors

Retrieved on: 
Wednesday, November 1, 2023
Knowledge, MedlinePlus, Faculty, Royal College of Physicians and Surgeons of Canada, Health, Surgeon, University, AB, Alberta Health Services, Stollery Children's Hospital, EPCOR, Royal college, Medicine, Physician, Executive, Teaching, Public, Nephrology, Patient, Hospital, International Pediatric Nephrology Association, Pediatrics, Nursing

EDMONTON, AB, Nov. 1, 2023 /CNW/ - EPCOR Utilities Inc. (EPCOR) is pleased to announce the appointment of Dr. Verna Yiu to its Board of Directors.

Key Points: 
  • EDMONTON, AB, Nov. 1, 2023 /CNW/ - EPCOR Utilities Inc. (EPCOR) is pleased to announce the appointment of Dr. Verna Yiu to its Board of Directors.
  • "Dr. Yiu is highly recognized for her dedication and leadership in the fields of medicine and academia, as well as for her commitment to advancing the health and outlook of the patients in her care and the communities she serves," said Janice G. Rennie, EPCOR Board Chair.
  • We are fortunate and pleased to welcome her to our Board."
  • In addition to previous faculty leadership roles at the University of Alberta, Dr. Yiu served as the Executive Vice-President and Chief Medical Officer (2012-2016) and then as the President and CEO (2016-2022) of Alberta Health Services.

Evergreen Nephrology and Nephrology Associates of Central Florida Partnering to Bring a New Standard of Kidney Care to Patients

Retrieved on: 
Tuesday, August 15, 2023
Partnership, Evergreen, Nephrology, CKD, MD, Chronic kidney disease, Patient, International Pediatric Nephrology Association, Kidney disease, Nursing, Central Florida

NASHVILLE, Tenn., Aug. 15, 2023 /PRNewswire/ -- Evergreen Nephrology and Nephrology Associates of Central Florida announce a partnership to raise the standard of kidney care in the Orlando area.

Key Points: 
  • NASHVILLE, Tenn., Aug. 15, 2023 /PRNewswire/ -- Evergreen Nephrology and Nephrology Associates of Central Florida announce a partnership to raise the standard of kidney care in the Orlando area.
  • Evergreen Nephrology and Nephrology Associates of Central Florida will offer a patient-centered approach to CKD.
  • "Working as a team, Evergreen Nephrology and Nephrology Associates of Central Florida will offer a new, patient-centered approach to caring for those living with chronic kidney disease in Central Florida, ensuring that each patient receives care that is tailored to their specific needs."
  • "Our team at Nephrology Associates of Central Florida is excited to partner with Evergreen Nephrology to provide care and support in an effort to change the outlook for patients in their kidney care journey," said Uday Ranjit, MD.

Evergreen Nephrology and Hypertension Nephrology Associates, P.C. Partner

Retrieved on: 
Tuesday, July 18, 2023
P.C, Partnership, Evergreen, Chronic kidney disease, Education, Nephrology, International Pediatric Nephrology Association, Overalls, Quality of life, Hope, Prognosis, DO, Patient, Transport, Health, CKD, Kidney disease, Hypertension, Disease, Pharmaceutical industry, Nursing

NASHVILLE, Tenn., July 18, 2023 /PRNewswire/ -- Evergreen Nephrology is pleased to announce a joint venture with Hypertension Nephrology Associates, P.C., a nephrology practice specializing in providing kidney care for those in the Detroit metropolitan area.

Key Points: 
  • NASHVILLE, Tenn., July 18, 2023 /PRNewswire/ -- Evergreen Nephrology is pleased to announce a joint venture with Hypertension Nephrology Associates, P.C., a nephrology practice specializing in providing kidney care for those in the Detroit metropolitan area.
  • Evergreen partners with nephrology groups like Hypertension Nephrology Associates to offer seamless and coordinated support to help those living with the disease – people like John Taylor.
  • "We are proud to team up with Hypertension Nephrology Associates to offer a multi-dimensional approach to caring for those living with chronic kidney disease in Detroit.
  • "Hypertension Nephrology Associates is excited to partner with Evergreen Nephrology to further our commitment to providing our patients with optimal care," said Jason Biederman, DO, President of Hypertension Nephrology Associates.

International Covid Memorial Monument Design Competition Underway

Retrieved on: 
Tuesday, May 2, 2023
Vaccine, Commissioner, Yale University, Education, Face, Big Spring Vietnam Memorial, International Pediatric Nephrology Association, COVID-19, Ludvig Hektoen, Hope, Research, Vietnam Veterans Memorial, Science, Interest, Nephrology, Patient, Nursing, Courage, Environment, Family office, Social media, Pharmaceutical industry, Tourism

CHICAGO, May 02, 2023 (GLOBE NEWSWIRE) -- An international design competition is underway for a Covid memorial monument.

Key Points: 
  • CHICAGO, May 02, 2023 (GLOBE NEWSWIRE) -- An international design competition is underway for a Covid memorial monument.
  • The final design will determine in part where the monument will be constructed, however negotiations are underway for a permanent site.
  • The winning design will provide a moving and creative concept that speaks to nations and cultures everywhere.
  • Commissioner Vice Chair, William E. Richards, an investment and Family Office executive, draws parallels to the design competition for the Vietnam Memorial in Washington, D.C. more than 40 years ago.

JelloX Biotech Opens New Horizons for AI-Powered 3D Pathology

Retrieved on: 
Friday, March 31, 2023
Harvard University, International Pediatric Nephrology Association, Marie Cassidy, 3D, Deep learning, Pathology, Cancer, Prognosis, Research, Medicine, Lupus, H&E, Inflammation, Nephrology, Nephritis, Patient, SAN, Kidney, Lupus nephritis, Hospital, AI, Breast cancer, Disease, Medical imaging

SAN FRANCISCO, March 31, 2023 /PRNewswire/ -- JelloX Biotech Inc., a Taiwan-based startup focused on cancer pathology, announced involvement with two new research breakthroughs that demonstrate expanded potential for its specialized technology combining 3D imaging and AI.

Key Points: 
  • SAN FRANCISCO, March 31, 2023 /PRNewswire/ -- JelloX Biotech Inc., a Taiwan-based startup focused on cancer pathology, announced involvement with two new research breakthroughs that demonstrate expanded potential for its specialized technology combining 3D imaging and AI.
  • While focusing mainly on cancer-specific applications, JelloX believes strongly in the possibilities of 3D imaging and AI.
  • This included Dr. Lin-Shien Fu, Director of the Pediatric Nephrology and Immunology Department at Taiwan's Taichung Veterans General Hospital, whose recent work highlights new potential of 3D pathology.
  • released a paper that showed that 3D pathology can facilitate pathological analysis of kidney inflammation from lupus, also known as lupus nephritis.

CareDx Presents Latest Advancements at 12th Congress of the International Pediatric Transplant Association

Retrieved on: 
Thursday, March 23, 2023
Cardiology, Biotechnology, Surgery, Health, Medical Devices, Children, Hospitals, Consumer, UPMC Children's Hospital of Pittsburgh, Heart, Medicine, International Pediatric Nephrology Association, University of Texas Health Science Center at San Antonio, Research fellow, UT Health San Antonio Cancer Center, MBA, Research, Associate, MS, Science, Congress, Assistant professor, Publication, Patient, Physician, FAHA, Washington University School of Medicine, Kidney, Heart failure, Hospital, IPTA, BK virus, BK, Caregiver, Dentistry, Nursing, Pediatrics, MD

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its gold-level sponsorship and participation at the 12th Congress of the International Pediatric Transplant Association (IPTA) taking place March 25-28, 2023, in Austin, Texas.

Key Points: 
  • CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its gold-level sponsorship and participation at the 12th Congress of the International Pediatric Transplant Association (IPTA) taking place March 25-28, 2023, in Austin, Texas.
  • “CareDx is 100% committed to driving transplant innovation and this is especially important for pediatric patients who require decades of graft function.
  • “We are very proud to once again be one of the lead sponsors for the 12th Congress of the IPTA – an organization at the forefront of advancing science and technology for pediatric patients.”
    CareDx will host a symposium highlighting the company’s latest developments in pediatric heart and kidney transplant patient care.
  • The symposium, “Paradigm Shifts in Pediatric Surveillance Testing: AlloSure and AlloMap in Action” will be held on Sunday, March 26, from 12:30 – 1:30pm CDT.

The 10th Annual International Pediatric Feeding Disorder Conference Unites 58 prominent Feeding and Therapy experts and more than 80 authors

Retrieved on: 
Friday, March 17, 2023
CE, Loss, International, University, Life, Francine Shapiro, Ventricular septal defect, Psychiatric-mental health nurse practitioner, PLLC, International Pediatric Nephrology Association, Trauma, Feeding disorder, Research, Private practice, University of North Carolina at Pembroke, PMHNP, APRN, Grief, Publication, Patient, Child, Matter, EMDR, PFD, Fairfield University, Family, Conference, Nursing, PHOENIX

PHOENIX, March 16, 2023 /PRNewswire-PRWeb/ -- Arizona-based nonprofit Feeding Matters, the first organization in the world dedicated to advancing the system of care for pediatric feeding disorder (PFD) is proud to host the upcoming 10th annual International Pediatric Feeding Disorder Conference (IPFDC). The IPFDC 2023 will be streamed live April 13-14, 2023, with pre-conference events on April 12, and will offer the most diverse group of speakers and lightning talk authors to date. All sessions will be available on-demand through May 31, 2023.

Key Points: 
  • Arizona-based nonprofit Feeding Matters, the first organization in the world dedicated to advancing the system of care for pediatric feeding disorder (PFD) is proud to host the upcoming 10th annual International Pediatric Feeding Disorder Conference (IPFDC).
  • PHOENIX, March 16, 2023 /PRNewswire-PRWeb/ -- Arizona-based nonprofit Feeding Matters, the first organization in the world dedicated to advancing the system of care for pediatric feeding disorder (PFD) is proud to host the upcoming 10th annual International Pediatric Feeding Disorder Conference (IPFDC).
  • This year's conference will bring together a lineup of the pediatric feeding community's foremost experts, leaders, and contributors.
  • To secure your registration or see the complete schedule with session descriptions for the year's most prolific and informative pediatric feeding conference, visit International Pediatric Feeding Disorder Conference.

Strive Health Doubles Its Footprint in Innovative Medicare Payment Model, Surpasses $2.5 Billion of Medical Spend Under Management

Retrieved on: 
Thursday, February 23, 2023
Hospitals, Health, Practice Management, Managed Care, Health Insurance, Social, Kidney disease, Consultant, Nephrology, Chronic kidney disease, Senior, Striving, Growth, Disease, International Pediatric Nephrology Association, Patient satisfaction, Partnership, ESKD, Risk, Kidney failure, KCE, Renal replacement therapy, Trinity Health, Patient, Medicare, Catholic Church, CMMI, CKD, Practitioner, Multimedia, Hospital, Center for Medicare and Medicaid Innovation, Pharmaceutical industry, Health insurance, Nursing

Strive Health , the national leader in value-based kidney care, doubled its footprint year over year in Medicare’s innovative payment model for people with kidney disease.

Key Points: 
  • Strive Health , the national leader in value-based kidney care, doubled its footprint year over year in Medicare’s innovative payment model for people with kidney disease.
  • View the full release here: https://www.businesswire.com/news/home/20230223005022/en/
    The United States currently spends $420 billion annually on patients with kidney disease, and 24% of Medicare spending is on patients with kidney disease.
  • The United States currently spends $420 billion annually on patients with kidney disease, and 24% of Medicare spending is on patients with kidney disease.
  • In January, Strive also announced a partnership with Trinity Health , one of the nation’s largest not-for-profit Catholic health systems.

New Paper Highlights Clinical Utility of Natera’s Renasight™ Test in the Management of Kidney Disease

Retrieved on: 
Thursday, February 2, 2023
Health, Genetics, Health Technology, Other Health, Clinical Trials, Biotechnology, DNA, Kidney, Pediatrics, MSCE, Broad Institute, Augusta University Medical Center, Sickle cell disease, ADPKD, Diagnosis, Chronic kidney disease, Boston, Genetic testing, Polycystic kidney disease, National Kidney Foundation, Patient, Hospital, Nephrology, Harvard Medical School, The New England Journal of Medicine, NTRA, Associate, Medicine, Gene, Kidney disease, Manuscript, SCD, Pharmaceutical industry, Nursing, Natera, International Pediatric Nephrology Association, MD

This paper reviews the case of a 16-year-old patient with sickle cell disease (SCD) and kidney cysts.

Key Points: 
  • This paper reviews the case of a 16-year-old patient with sickle cell disease (SCD) and kidney cysts.
  • Natera’s Renasight test, a genetic testing panel that analyzes 385 genes related to kidney disease, was administered to examine whether an additional genetic cause may have been contributing to the patient’s kidney cysts.
  • The test identified genetic variants which led to a diagnosis of autosomal dominant polycystic kidney disease (ADPKD), in addition to the patient’s SCD.
  • Genetic testing is providing care teams with key insights that will better inform disease management and potentially slow disease progression for patients with kidney disease.”
    Chronic kidney disease affects more than 10% of the global population.